Orbis Medicines, an oral macrocycle drug discovery company, closed a €90 million Series A funding round, bringing the total amount raised by the company to €116 million. The funds will support the development of Orbis’ pipeline of next-gen oral macrocycle drugs, called ‘nCycles.’ This financing was led by New Enterprise Associates with participation from new investors including Eli Lilly and Co., Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and For...